Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe.
Moderate growth potential and slightly overvalued.
Share Price & News
How has Trinity Biotech's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TRIB's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: TRIB matched the US Medical Equipment industry which returned 15.6% over the past year.
Return vs Market: TRIB exceeded the US Market which returned 12.5% over the past year.
Price Volatility Vs. Market
How volatile is Trinity Biotech's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StIs Trinity Biotech (NASDAQ:TRIB) A Risky Investment?
1 month ago | Simply Wall StDid You Manage To Avoid Trinity Biotech's (NASDAQ:TRIB) Devastating 90% Share Price Drop?
2 months ago | Simply Wall StHow Does Trinity Biotech plc (NASDAQ:TRIB) Affect Your Portfolio Volatility?
Is Trinity Biotech undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: TRIB ($2.49) is trading below our estimate of fair value ($7.59)
Significantly Below Fair Value: TRIB is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: TRIB is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: TRIB is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TRIB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TRIB is overvalued based on its PB Ratio (67.8x) compared to the US Medical Equipment industry average (4x).
How is Trinity Biotech forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TRIB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: TRIB is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: TRIB's is expected to become profitable in the next 3 years.
Revenue vs Market: TRIB's revenue (1.3% per year) is forecast to grow slower than the US market (9.3% per year).
High Growth Revenue: TRIB's revenue (1.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TRIB's Return on Equity is forecast to be high in 3 years time
How has Trinity Biotech performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TRIB is currently unprofitable.
Growing Profit Margin: TRIB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TRIB is unprofitable, and losses have increased over the past 5 years at a rate of 42.5% per year.
Accelerating Growth: Unable to compare TRIB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TRIB is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (2.5%).
Return on Equity
High ROE: TRIB has a negative Return on Equity (-4026.69%), as it is currently unprofitable.
How is Trinity Biotech's financial position?
Financial Position Analysis
Short Term Liabilities: TRIB's short term assets ($67.5M) exceed its short term liabilities ($22.1M).
Long Term Liabilities: TRIB's short term assets ($67.5M) do not cover its long term liabilities ($106.3M).
Debt to Equity History and Analysis
Debt Level: TRIB's debt to equity ratio (8077.6%) is considered high.
Reducing Debt: TRIB's debt to equity ratio has increased from 1.2% to 8077.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TRIB has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if TRIB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Trinity Biotech current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TRIB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TRIB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TRIB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TRIB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: TRIB is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TRIB's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Ronan O’Caoimh (64yo)
Mr. Ronan O'Caoimh co-founded Trinity Biotech PLC in June 1992 and has been its Chief Executive Officer since October 2008. Mr. O'Caoimh served as Chief Executive Officer of Trinity Biotech PLC from March ...
CEO Compensation Analysis
Compensation vs Market: Ronan's total compensation ($USD425.00K) is below average for companies of similar size in the US market ($USD608.75K).
Compensation vs Earnings: Ronan's compensation has been consistent with company performance over the past year.
|Chairman & CEO||11.83yrs||US$425.00k||8.44% $4.4m|
|Chief Financial & Accounting Officer||3.92yrs||US$630.00k||0.18% $93.4k|
|Executive Director||13.58yrs||no data||1.92% $997.4k|
|Independent Non-Executive Director||11.75yrs||US$75.00k||0.37% $191.7k|
|Lead Independent Director||no data||US$75.00k||no data|
|Independent Non-Executive Director||11.5yrs||US$75.00k||no data|
Experienced Board: TRIB's board of directors are seasoned and experienced ( 11.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Trinity Biotech plc's company bio, employee growth, exchange listings and data sources
- Name: Trinity Biotech plc
- Ticker: TRIB
- Exchange: NasdaqGS
- Founded: 1992
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$52.045m
- Shares outstanding: 20.90m
- Website: https://www.trinitybiotech.com
Number of Employees
- Trinity Biotech plc
- IDA Business Park
- Co. Wicklow
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|TRIB||NasdaqGS (Nasdaq Global Select)||Yes||ADR EACH REPR 4 CLS'A'ORD USD0.019||US||USD||Oct 1992|
|TRBA||DB (Deutsche Boerse AG)||Yes||ADR EACH REPR 4 CLS'A'ORD USD0.019||DE||EUR||Oct 1992|
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. The company sells its products through its direct sales force; and a network of independent distributors and strategic partners. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/02 23:33|
|End of Day Share Price||2020/07/31 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.